Amgen 2Q Revenues:  $5.8 billion (+2%) 2Q Earnings: $2.2 billion (+15%) YTD Revenues: $11.3 billion (flat) YTD Earnings: $4.2 billion (+12%) Comments: Growth in the quarter was driven by Prolia, up 15% to $505 million, Repatha sales of $83 million, and KYPROLIS sales were up 23% to $211 million, helping to offset losses for Neulasta (down 5% to $1.1 billion), NEUPOGEN (down 30% to $137 million), and EPOGEN sales (down 12% to $292 million). BLINCYTO sales increased 43% to $43 million. Sensip...